Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial

Lancet Neurology

Volumn 5, Issue 6, 2006, Pages 493-500

  Gonzalez, Henrik ^a,b   Stibrant Sunnerhagen, Katharina ^c   Sjöberg, Inger ^d   Kaponides, Georgios ^a,b   Olsson, Tomas ^e   Borg, Kristian ^a,b  

^a Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

ADULT; AGED; AGING; ARTICLE; CHRONOTHERAPY; CLINICAL TRIAL; COLD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH CENTER; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MEASUREMENT; MULTICENTER STUDY; MULTIDIMENSIONAL SCALING; MUSCLE STRENGTH; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT MONITORING; PHYSICAL ACTIVITY; POPULATION RESEARCH; POSTPOLIOMYELITIS SYNDROME; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REGISTER; RIGOR; SCORING SYSTEM; SELF REPORT; SHORT FORM 36; SIDE EFFECT; SKIN DISEASE; SLEEP; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS TISSUE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNIVERSITY; VISUAL ANALOG SCALE; WALKING;

AGED; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; POSTPOLIOMYELITIS SYNDROME; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WALKING;

EID: 33646507921     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70447-1     Document Type: Article

References (40)

1. Halstead L., and Rossi C. New problems in old polio patients: results of a survey of 539 polio survivors. Orthopedics 8 (1985) 845-850
2. McComas A., Quartly C., and Griggs R. Early and late losses of motor units after poliomyelitis. Brain 120 (1997) 1415-1421
3. Grimby G., Stalberg E., Sandberg A., and Stibrant Sunnerhagen K. An 8-year longitudinal study of muscle strength, muscle fiber size, and dynamic electromyogram in individuals with late polio. Muscle Nerve 21 (1998) 1428-1437
4. Gonzalez H., Khademi M., Andersson M., Wallstrom E., Borg K., and Olsson T. Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 205 (2002) 9-13
5. Gonzalez H., Khademi M., Andersson M., et al. Prior poliomyelitis-IvIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 150 (2004) 139-144
6. Miller D. Post-polio syndrome spinal cord pathology: case report with immunopathology. Ann N Y Acad Sci 753 (1995) 186-193
7. Dalakas M., Pezeshkpour G., and Flaherty M. Progressive nemaline (rod) myopathy associated with HIV infection. N Engl J Med 317 (1987) 1602-1603
8. Dalakas M., and Illa I. Post-polio syndrome: concepts in clinical diagnosis, pathogenesis, and etiology. Adv Neurol 56 (1991) 495-511
9. Dalakas M. Morphologic changes in the muscles of patients with postpoliomyelitis neuromuscular symptoms. Neurology 38 (1988) 99-104
10. Sun D., Newman T., Perry V., and Weller R. Cytokine-induced enhancement of autoimmune inflammation in the brain and spinal cord: implications for multiple sclerosis. Neuropathol Appl Neurobiol 30 (2004) 374-384
11. Horemans H., Nollet F., Beelen A., et al. Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement. J Neurol Neurosurg Psychiatry 74 (2003) 1655-1661
12. Kaponides G., Gonzalez H., Olsson T., and Borg K. Effect of intravenous immunoglobulin in patients with post-polio syndrome: an uncontrolled pilot study. J Rehabil Med 38 (2006) 138-140
13. Halstead L., and Rossi C. Post-polio syndrome: clinical experience with 132 consecutive outpatients. Birth Defects Orig Artic Ser 23 (1987) 13-26
14. Halstead L., Gawne A., and Pham B. National rehabilitation hospital limb classification for exercise, research, and clinical trials in post-polio patients. Ann N Y Acad Sci 753 (1995) 343-353
15. Coons S., Rao S., Keininger D., and Hays R. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 17 (2000) 13-35
16. Meyer-Rosberg K., Burckhardt C., Huizar K., Kvarnstrom A., Nordfors L., and Kristofferson A. A comparison of the SF-36 and Nottingham health profile in patients with chronic neuropathic pain. Eur J Pain 5 (2001) 391-403
17. Harada N., Chiu V., and Stewart A. Mobility-related function in older adults: assessment with a 6-minute walk test. Arch Phys Med Rehabil 80 (1999) 837-841
18. Steffen T., Hacker T., and Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: six-minute walk test, Berg balance scale, timed up and go test, and gait speeds. Phys Ther 82 (2002) 128-137
19. Lin M., Hwang H., Hu M., Wu H., Wang Y., and Huang F. Psychometric comparisons of the timed up and go, one-leg stand, functional reach, and Tinetti balance measures in community-dwelling older people. J Am Geriatr Soc 52 (2004) 1343-1348
20. Washburn R., McAuley E., Katula J., Mihalko S., and Boileau R. The physical activity scale for the elderly (PASE): evidence for validity. J Clin Epidemiol 52 (1999) 643-651
21. Price D., Bush F., Long S., and Harkins S. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain 56 (1994) 217-226
22. Smets E., Garssen B., Bonke B., and De Haes J. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39 (1995) 315-325
23. Spira P., and Beran R. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 61 (2003) 1753-1759
24. Sullivan M., and Karlsson J. The Swedish SF-36 health survey III-evaluation of criterion-based validity: results from normative population. J Clin Epidemiol 51 (1998) 1105-1113
25. Trojan D., Collet J., Shapiro S., et al. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology 53 (1999) 1225-1233
26. Agre J., Grimby G., Rodriquez A., Einarsson G., Swiggum E., and Franke T. A comparison of symptoms between Swedish and American post-polio individuals and assessment of lower limb strength-a four-year cohort study. Scand J Rehabil Med 27 (1995) 183-192
27. Stolwijk-Swuste J., Beelen A., Lankhorst G., and Nollet F. The course of functional status and muscle strength in patients with late-onset sequelae of poliomyelitis: a systematic review. Arch Phys Med Rehabil 86 (2005) 1693-1701
28. Dalakas M. Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations. Ann N Y Acad Sci 753 (1995) 167-185
29. Halstead L. Post-polio syndrome. Sci Am 278 (1998) 42-47
30. Dinsmore S., Dambrosia J., and Dalakas M. A double-blind, placebo-controlled trial of high-dose prednisone for the treatment of post-poliomyelitis syndrome. Ann N Y Acad Sci 753 (1995) 303-313
31. Dalakas M., Aksamit A., Madden D., and Sever J. Administration of recombinant human leukocyte alpha 2-interferon in patients with amyotrophic lateral sclerosis. Arch Neurol 43 (1986) 933-935
32. Andersson J., Skansen-Saphir U., Sparrelid E., and Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104 suppl 1 (1996) 10-20
33. Campbell I. Neuropathogenic actions of cytokines assessed in transgenic mice. Int J Dev Neurosci 13 (1995) 275-284
34. Smith T., Groom A., Zhu B., and Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6 (2000) 62-66
35. Colbere-Garapin F., Duncan G., Pavio N., Pelletier I., and Petit I. An approach to understanding the mechanisms of poliovirus persistence in infected cells of neural or non-neural origin. Clin Diagn Virol 9 (1998) 107-113
36. Dalakas M. The post-polio syndrome as an evolved clinical entity: definition and clinical description. Ann N Y Acad Sci 753 (1995) 68-80
37. Julien J., Leparc-Goffart I., Lina B., et al. Postpolio syndrome: poliovirus persistence is involved in the pathogenesis. J Neurol 246 (1999) 472-476
38. Roivainen M., Kinnunen E., and Hovi T. Twenty-one patients with strictly defined postpoliomyelitis syndrome: no poliovirus-specific IgM antibodies in the cerebrospinal fluid. Ann Neurol 36 (1994) 115-116
39. Melchers W., de Visser M., Jongen P., et al. The postpolio syndrome: no evidence for poliovirus persistence. Ann Neurol 32 (1992) 728-732
40. Jubelt B., Salazar-Grueso E., Roos R., and Cashman N. Antibody titer to the poliovirus in blood and cerebrospinal fluid of patients with post-polio syndrome. Ann N Y Acad Sci 753 (1995) 201-207